文献速递角膜与眼表疾病

先天性无虹膜相关角膜病变的管理:三级转诊中心的长期结局

Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.
PubMed 文献 · Am J Ophthalmol · 2019-11-12

回顾性比较病例系列研究纳入47例先天性无虹膜患者共92眼,平均年龄48.0±18.0岁、平均随访78.6±42.2个月。AAK III-V期行角膜缘干细胞移植(LSCT)和Boston人工角膜(KPro)后appETDRS评分中位数从2(95%CI 0-20)提高至26(95%CI 15-41)(P=0.0004);I-II期药物管理视力稳定。个体化药物与先进手术干预可保持并改善视力。

要点

  • AAK I-II期药物管理后视力保持稳定,appETDRS评分26(20-35)至35(26-35)(P>0.05)。
  • AAK III-V期行LSCT和KPro后appETDRS评分中位数从2(0-20)升至26(15-41)(P=0.0004)。
  • LSCT后appETDRS评分从20(0-35)升至30(20-55)(P=0.021),KPro后从2(0-20)至2(0-41)但95%CI改善(P=0.019)。

核心结论

  • 通过适当的AAK特征描述与分期,个体化药物与先进手术干预可保持并改善视力。

研究设计与样本

  • 回顾性比较病例系列研究,回顾性审查先天性无虹膜患者病历。
  • 共纳入47例患者92眼(女性31例),平均年龄48.0±18.0岁,平均随访78.6±42.2个月。

主要发现

  • 初诊时AAK I期12眼(13%)、II期33眼(35.9%)、III期25眼(27.2%)、IV期17眼(18.5%)、V期5眼(5.4%)。
  • AAK III-V期常行LSCT和Boston KPro,这些先进角膜手术使appETDRS评分中位数(95%CI)从2(0-20)提高至26(15-41)(Snellen值20/20,000至20/300;P=0.0004)。
  • AAK I-II期患者接受药物治疗,至末次随访视力稳定(appETDRS评分26[20-35]至35[26-35];Snellen 20/300至20/200;P>0.05)。
  • LSCT后appETDRS视力当量从20(0-35)提高至30(20-55)(Snellen 20/400至20/250;P=0.021)。
  • KPro后appETDRS视力当量从2(0-20)至2(0-41)(Snellen 20/20,000),随访后95%CI改善(P=0.019)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the outcomes of medical and surgical management for congenital aniridia-associated keratopathy (AAK) over a long-term follow-up period. DESIGN: Retrospective, comparative case series. METHODS: Medical records of patients diagnosed with congenital aniridia were retrospectively reviewed. Age, sex, ethnicity, follow-up time, AAK stage, noncorneal abnormalities, ocular surgeries, and complications were recorded. The visual acuity equivalent (VAE), approximate Early Treatment Diabetic Retinopathy Study (appETDRS) letter score, was calculated using recorded Snellen visual acuities. RESULTS: A total of 92 eyes of 47 patients (31 females) with mean age of 48.0 ± 18.0 years and mean follow-up of 78.6 ± 42.2 months were included. At the initial visit, 12 eyes (13%) were classified as Stage I AAK, 33 eyes (35.9%) were Stage II, 25 eyes (27.2%) were Stage III, 17 eyes (18.5%) were Stage IV, and 5 eyes (5.4%) were Stage V. Limbal stem cell transplantation (LSCT) and Boston keratoprosthesis (KPro) were frequently performed in eyes with Stages III-V. These advanced corneal surgeries significantly improved the median (95% confidence interval [CI]) of calculated appETDRS scores from 2 (0-20) to 26 (15-41) (Snellen values, 20/20,000 to 20/300; P = 0.0004). Patients with earlier Stages (I-II) of AAK were managed medically and had stable visual acuity through their final visits (appETDRS score of 26 [20-35] to 35 [26-35]; Snellen, 20/300 to 20/200; P > 0.05). The appETDRS VAE was significantly improved from 20 (0-35) to 30 (20-55), Snellen, 20/400 to 20/250, following LSCT (P = 0.021) and from 2 (0-20) to 2 (0-41) after KPro; Snellen, 20/20,000 VAE but with improved 95% CI after follow-up (P = 0.019). CONCLUSIONS: With proper characterization and staging of AAK, individualized medical and advanced surgical interventions preserves and improves visual acuity.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Yazdanpanah G, Bohm KJ, Hassan OM, et al. Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center. Am J Ophthalmol. 2019. PMID: 31730836. doi:10.1016/j.ajo.2019.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。